#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden 0.5 hours per response..

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may

\$ 11

Common

Stock (1) <u>(2)</u>

Warrants

purchase

Common

Stock (1)

12/08/2017

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment

1(b).	uc. See msur			` /		Con	npan	y A	ct of	1940			` '						
		Reporting Person *				Name an				0 ,				Relationship of		all applicat			
(Las		(First) O AVENUE, 2N	(Middle) D FLOOR		e of	Earliest 7								Officer (give tit	le below) Co-Chief I	Ot	her (spe	cify below)	
		(Street)			mer	ndment, I	Date O	Origi	nal File	d(Month/	Day/Year)	)	_X_	ndividual or Jo Form filed by One Form filed by Mor	Reporting Pers	on	Applica	ble Line)	
ALHAM (Cit	BRA, CA	91801 (State)	(Zip)																
		(State)	2. Transaction	24 D			T 3. Tra						- 1	, Disposed of,				7. Natu	
1.Title of Security (Instr. 3)		Date (Month/Day/Year	Execu any	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr. 8)			4. Securities Acquor Disposed of (D (Instr. 3, 4 and 5)		f (D)	Own Tran	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			wners orm: orect (	hip Indirect Benefic	cial ship	
							Co	ode	V	Amo			Price				nstr. 4	.)	
Common	Stock (1)	<u>2</u> )	12/08/2017				J <sup>C</sup>	2)		1,664	4,054 A	A	(2) 1,66	64,054		I		Medio	cians ornia, ssional cal oration
Reminder: I	Report on a s	eparate line for each	class of securities b	e II - Dei	rivat		rities	Acq	Pe thi cu juired,	rsons s form rrently Dispose	are no valid (	ot requi OMB co r Benefi	ired to res ontrol nun					SEC 147	74 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code	tion	5. Numb	per of ive es ed (A) ed of (I	or D)	6. Date Expira		sable an		7. Title an	d Amount of g Securities d 4)	8. Price of Derivative Security (Instr. 5)	ve Derivative Securities Beneficially Ownership Form of Benefic Ownership Ownership Form of Derivative Owners	11. Natur of Indirec Beneficia Ownershi (Instr. 4)		
				Code	V	(A)		(D)	Date Exercis	sable	Expira Date	tion	Title	Amount or Number of Shares					
Warrants to purchase Common Stock (1)	\$ 0	12/08/2017		J(3)		68,317	7.43		10/14	-/2015	10/14	1/2020	Common Stock	<sup>1</sup> 68,317.43	(3)	68,317	.43	I	By Allied
Warrants to purchase Common Stock (1)	\$ 10	12/08/2017		J <u>(3)</u>		34,158	3.69		03/30	)/2016	03/30	)/2021	Common Stock	34,158.69	(3)	34,158	.69	I	By Allied
Warrants to purchase Common	<b># 10</b>	12/08/2017		J <sup>(2)</sup>		55,337	7.13		12/08	3/2017	12/08	3/2022	Commo	<sup>1</sup> 55,337.13	(2)	55,337	1.13	I	By Allied

52,262.84

J(2)

12/08/2017 12/08/2022

Stock

Common

Stock

52,262.84

<u>(2)</u>

52,262.84

<u>(1)</u>

Ву

(1)

Allied

Ι

## **Reporting Owners**

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Lam Thomas S. 1668 S. GARFIELD AVENUE 2ND FLOOR ALHAMBRA, CA 91801	X		Co-Chief Executive Officer					

# **Signatures**

/s/ Thomas S. Lam, M.D.	12/18/2017	
**Signature of Reporting Person	Date	

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- These shares and warrants are owned directly by Allied Physicians of California, A Professional Medical Corporation ("Allied"), of which Reporting Person is a director, officer and shareholder.

  (1) Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the filing of this report is not an admission that Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.
- On December 8, 2017, a reverse merger transaction between the Issuer and Network Medical Management, Inc. ("NMM") was consummated such that NMM became a wholly-owned subsidiary of the Issuer (the "Merger"). Immediately prior to the closing of the Merger (the "Closing"), Allied was a shareholder of NMM. Pursuant to the Merger, the shares of NMM common stock previously
- (2) held by Allied were converted into (i) 1,664,054 shares of common stock of the Issuer, (ii) a warrant to purchase 52,262.84 shares of common stock of the Issuer at an exercise price of \$11.00 per share, (iii) a warrant to purchase 55,337.13 shares of common stock of the Issuer at an exercise price of \$10.00 per share, (iv) cash in lieu of fractional shares, and (v) Allied's pro rata portion, if any, of the holdback shares of common stock of the Issuer (such pro rata portion of the holdback shares would, without offset, initially be equal to 184,894.80 shares of common stock of the Issuer).
- Immediately prior to the Closing, NMM made an in-kind distribution on a pro rata basis to its shareholders (including Allied) of the following warrants, which warrants were previously held by NMM: (i) 1,111,111 Series A warrants (of which Allied will receive 68,317.43 Series A warrants) to purchase common stock of the Issuer, exercisable at any time prior to October 14, 2020 at an exercise price of \$9.00 per share, and (ii) 555,555 Series B warrants (of which Allied will receive 34,158.69 Series B warrants) to purchase common stock of the Issuer, exercisable at any time prior to March 30, 2021 at an exercise price of \$10.00 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.